#United States #Phoenix #gene therapy #Akadeum Life Sciences #Cell Separation

Akadeum Life Sciences Showcases Innovations at the Cell & Gene Meeting on the Mesa

Akadeum Life Sciences is set to make waves at the annual Cell & Gene Meeting on the Mesa, taking place from October 6 to 8, 2025, at the renowned Arizona Biltmore Resort in Phoenix. The company's innovative approach to buoyancy-based cell separation technology promises to revolutionize the industry, offering significant updates on its next-generation microbubble technology.

Leading the Conversation on Therapeutics Development

One of the highlights of the event will be a panel titled "Quality, Speed, Cost – Pick Three" moderated by Dr. Bill Lloyd, Akadeum's Vice President of Research and Development. This session will bring together prominent industry leaders to dialogue about reducing development time and costs in therapeutics while ensuring high-quality results. Dr. Lloyd's expertise, along with insights from the panelist lineup — including Jason Bock, PhD, CEO of CTMC, and Shannon Eaker, CTO of Xcell Biosciences — will underscore the urgent need for affordable and accessible therapeutic options. This is especially pertinent given that Akadeum's microbubble technology can potentially reduce cell therapy production costs by up to 40% and cut production time by up to four days, translating to potent and persistent cell therapies.

Groundbreaking Presentations

On October 7, 2025, Akadeum's CEO, Dr. Brandon McNaughton, is expected to deliver an impactful presentation detailing the company’s latest achievements in regulatory, clinical, and technical areas. Attendees will learn how Akadeum's microbubble-based cell separation platform addresses critical industry challenges such as time constraints, cost efficiency, and scalability, effectively empowering developers to create high-quality therapeutics.

Dr. McNaughton will present data collected from various collaborations that demonstrate improved efficacy in product development and a notable decrease in vein-to-vein time when utilizing microbubbles for cell isolation. He clearly emphasizes Akadeum's mission: "Our goal is to dismantle barriers so more patients can access life-altering therapies. We are thrilled to contribute to the future of cell and gene therapy."

Opportunities for Collaboration

Throughout the meeting, Akadeum's team will engage with participants, presenting opportunities for integrating microbubble technology into existing workflows. The ease of incorporating their cell separation technology minimizes the need for new equipment while maintaining high standards of Quality Management Systems (GMP). Interested attendees are encouraged to connect with key team members, including CEO Dr. Brandon McNaughton and CFO Jim Militello, through the partneringONE® platform or Akadeum's official website.

About Akadeum Life Sciences

Akadeum Life Sciences is committed to progressing cell separation technologies via its unique buoyancy microbubble platform. This innovation supports researchers in achieving superior yields, enhanced purity, and simplified processes across life sciences. The company's vision revolves around a future where advanced separation technologies unlock new pathways in diagnostics, therapeutics, and fundamental research. For more information, sa visit Akadeum's website.

As the Cell & Gene Meeting on the Mesa approaches, Akadeum Life Sciences stands poised to showcase its developments and foster discussions that could change the landscape of cell and gene therapy.